Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 7:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 739 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: STEP-UP Clear all
Terminated Phase 1 Interventional

Safety, Tolerability, PK, Dosimetry, MTD and Preliminary Efficacy of Intra-lesionally Injected AvidinOX, Followed by IV Escalating Doses of [177Lu]DOTA-biotin in Pts With Injectable Solid Tumors or Lymphomas

NCT03188328
View directory record Official record
Conditions
Inoperable Solid Tumors or Lymphomas
Interventions
AvidinOX, 177Lu-ST2210
Drug
Lead sponsor
Alfasigma S.p.A.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 19, 2026, 7:40 PM EDT
Completed Not applicable Interventional

Improving Blood Pressure Control Through the myBPmyLife mHealth Application

NCT05154929
View directory record Official record
Conditions
Hypertension
Interventions
Dietary and physical activity JITAI delivered through the myBPmyLife app, Control Group
Behavioral · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Ann Arbor, Michigan • Flint, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 19, 2026, 7:40 PM EDT
Completed Phase 1 Interventional

Dasotraline SEP360-105 Pediatric PK/PD Study

NCT02195167
View directory record Official record
Conditions
Pediatric Attention Deficit Hyperactivity Disorder
Interventions
Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
12
States / cities
Little Rock, Arkansas • Colorado Springs, Colorado • Hialeah, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Oct 19, 2026, 7:40 PM EDT
Terminated Phase 4 Interventional

Assessment of Valproate on Ethanol Withdrawal

NCT03235531
View directory record Official record
Conditions
Alcohol Dependence, Alcohol Withdrawal Syndrome, Trauma, Heavy Drinking, Alcohol Use Disorder
Interventions
Valproate, Lorazepam
Drug
Lead sponsor
CAMC Health System
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Charleston, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 19, 2026, 7:40 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Increasing Access to Smoking Cessation and Smoke Free Home Services for Low-Income Pregnant Women in Northeast Texas

NCT05051345
View directory record Official record
Conditions
Cigarette Smoking-Related Carcinoma
Interventions
Informational Intervention, Media Intervention, Questionnaire Administration, Smoking Cessation Intervention, Survey Administration, Telephone-Based Intervention, Tobacco Cessation Counseling
Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
191 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 19, 2026, 7:40 PM EDT
Completed Phase 4 Interventional Results available

A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)

NCT04085172
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Guanfacine hydrochloride (TAK-503), Atomoxetine hydrochloride, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
6 Years to 17 Years
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
20
States / cities
Dothan, Alabama • Anaheim, California • Imperial, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 19, 2026, 7:40 PM EDT
Recruiting Not applicable Interventional

Sequential and Comparative Evaluation of Pain Treatment Effectiveness Response

NCT04142177
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Pain EASE, Tailored exercise, Continued Care and Active Monitoring, Cognitive Behavioral Therapy (CBT), Spinal Manipulation Therapy (SMT), Yoga
Other · Procedure · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
2,529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
19
States / cities
Phoenix, Arizona • Loma Linda, California • Long Beach, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 19, 2026, 7:40 PM EDT
Completed Not applicable Interventional Results available

Effectiveness & Implementation of a Behavioral Intervention for Adherence and Substance Use in HIV Care in South Africa

NCT03529409
View directory record Official record
Conditions
Human Immunodeficiency Virus, Alcohol-Related Disorders, Drug Use
Interventions
Project Khanya
Behavioral
Lead sponsor
University of Maryland, College Park
Other
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
College Park, Maryland
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Oct 19, 2026, 7:40 PM EDT
Completed Early Phase 1 Interventional

Exercise in Methamphetamine Use Disorder Upregulation and Neural Function

NCT03709667
View directory record Official record
Conditions
Methamphetamine Abuse
Interventions
EX, CON
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 19, 2026, 7:40 PM EDT
Completed Phase 1Phase 2 Interventional

Melphalan and Stem Cell Transplant Before Total-Body Irradiation and Donor Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma

NCT00003954
View directory record Official record
Conditions
Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions
melphalan, autologous hematopoietic stem cell transplantation, autologous bone marrow transplantation, peripheral blood stem cell transplantation, total-body irradiation, cyclosporine, mycophenolate mofetil, therapeutic allogeneic lymphocytes
Drug · Procedure · Radiation + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
3
States / cities
Duarte, California • Denver, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 6, 2020 · Synced Oct 19, 2026, 7:40 PM EDT
Completed Phase 3 Interventional Results available

GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin

NCT00712673
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Lixisenatide (AVE0010), Placebo, Pen auto-injector, Metformin
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 19, 2026, 7:40 PM EDT
Active, not recruiting Phase 3 Interventional

Treating Polysubstance Use Using a Novel Digital Technology

NCT05766631
View directory record Official record
Conditions
Opioid Use, Opioid Use Disorder, Cocaine Use, Cocaine Use Disorder
Interventions
DynamiCare Health, Methadone Treatment-As-Usual
Behavioral · Drug
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 19, 2026, 7:40 PM EDT
Completed Phase 4 Interventional Results available

Anxiety and Depression in Epilepsy: A Treatment Study

NCT03464383
View directory record Official record
Conditions
Anxiety, Depression, Epilepsy
Interventions
Escitalopram 10mg, Referral to Psychiatry, Survey only
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 19, 2026, 7:40 PM EDT
Recruiting Phase 1 Interventional

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

NCT04771572
View directory record Official record
Conditions
Non Hodgkin Lymphoma, Richter Transformation, Multiple Myeloma, T-cell-prolymphocytic Leukemia, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myeodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Myelofibrosis, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Neoplasm in Blast Phase
Interventions
LP-118
Drug
Lead sponsor
Newave Pharmaceutical Inc
Industry
Eligibility
13 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
8
States / cities
Chicago, Illinois • Boston, Massachusetts • Chapel Hill, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 19, 2026, 7:40 PM EDT
Recruiting Not applicable Interventional

Evaluating Evidenced Based Options for PTSD Treatment

NCT06733376
View directory record Official record
Conditions
PTSD - Post Traumatic Stress Disorder
Interventions
Cognitive Processing Therapy, Prolonged Exposure, Skills Training for Affective and Interpersonal Regulation
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 19, 2026, 7:40 PM EDT
Active, not recruiting Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma

NCT04712097
View directory record Official record
Conditions
Relapsed or Refractory Follicular Lymphoma
Interventions
Mosunetuzumab, Lenalidomide, Rituximab, Tociluzumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
17
States / cities
Duarte, California • Atlanta, Georgia • Fort Wayne, Indiana + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 19, 2026, 7:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pragmatic Trial of WHT vs. PC-GE to Promote Non-Pharmacological Strategies to Treat Chronic Pain in Veterans

NCT04330365
View directory record Official record
Conditions
Chronic Pain
Interventions
Whole Health Team (WHT) Intervention Arm, Primary Care Group Education (PC-GE) Intervention Arm, Usual Primary Care (UPC) Arm
Behavioral
Lead sponsor
San Francisco Veterans Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
793 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
6
States / cities
San Francisco, California • West Haven, Connecticut • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 19, 2026, 7:40 PM EDT
Terminated Not applicable Interventional

Study of Stepped Palliative Care in Patients With Advanced Lung Cancer DF/HCC SOCIAL-BEHAVIORAL RESERACH PROTOCOL

NCT03220100
View directory record Official record
Conditions
Lung Cancer
Interventions
Stepped Palliative Care
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2019 · Synced Oct 19, 2026, 7:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

CVCTPlus: A Couples-Based Approach to Linkage to Care and ARV Adherence

NCT01772992
View directory record Official record
Conditions
HIV
Interventions
CVCTPLUS
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Male only
Enrollment
586 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
4
States / cities
Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Oct 19, 2026, 7:40 PM EDT
Recruiting Not applicable Interventional

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

NCT03723928
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8, Elevated CA15-3 or CEA or CA27-29
Interventions
Usual care disease monitoring, Serum Tumor Marker directed disease monitoring, Quality-of-Life Assessment, Anxiety Questionnaire Administration
Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
739 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2036
U.S. locations
709
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 456 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 19, 2026, 7:40 PM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug

NCT01565707
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
Solifenacin Succinate Suspension, Placebo, Urotherapy
Drug · Behavioral
Lead sponsor
Astellas Pharma Europe B.V.
Industry
Eligibility
5 Years to 17 Years
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Shreveport, Louisiana • Albany, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 19, 2026, 7:40 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Taxi STEP (Social Networks, Technology, and Exercise Through Pedometers)

NCT03010163
View directory record Official record
Conditions
Physical Conditioning
Interventions
Health Fair, Pedometer, Text Messaging, Social Network Support
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Male only
Enrollment
290 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 19, 2026, 7:40 PM EDT
Terminated Not applicable Interventional

Perception-Action Approach Intervention for Infants With Congenital Muscular Torticollis

NCT02907801
View directory record Official record
Conditions
Congenital Muscular Torticollis
Interventions
Perception-Action Approach
Behavioral
Lead sponsor
Rosalind Franklin University of Medicine and Science
Other
Eligibility
Up to 9 Months
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Anchorage, Alaska
Source: ClinicalTrials.gov public record
Updated Aug 13, 2018 · Synced Oct 19, 2026, 7:40 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD0186

NCT05694741
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
AZD0186, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 19, 2026, 7:40 PM EDT